静脉注射心脏干细胞衍生的外泌体可改善阿霉素诱导的扩张型心肌病的心脏功能障碍。
Intravenous Cardiac Stem Cell-Derived Exosomes Ameliorate Cardiac Dysfunction in Doxorubicin Induced Dilated Cardiomyopathy.
作者信息
Vandergriff Adam C, de Andrade James Bizetto Meira, Tang Junnan, Hensley M Taylor, Piedrahita Jorge A, Caranasos Thomas G, Cheng Ke
机构信息
Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27695, USA ; Joint Department of Biomedical Engineering, UNC-Chapel Hill and NC State University, Chapel Hill and Raleigh, NC, USA.
Molecular Biomedical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27695, USA.
出版信息
Stem Cells Int. 2015;2015:960926. doi: 10.1155/2015/960926. Epub 2015 Aug 17.
Despite the efficacy of cardiac stem cells (CSCs) for treatment of cardiomyopathies, there are many limitations to stem cell therapies. CSC-derived exosomes (CSC-XOs) have been shown to be responsible for a large portion of the regenerative effects of CSCs. Using a mouse model of doxorubicin induced dilated cardiomyopathy, we study the effects of systemic delivery of human CSC-XOs in mice. Mice receiving CSC-XOs showed improved heart function via echocardiography, as well as decreased apoptosis and fibrosis. In spite of using immunocompetent mice and human CSC-XOs, mice showed no adverse immune reaction. The use of CSC-XOs holds promise for overcoming the limitations of stem cells and improving cardiac therapies.
尽管心脏干细胞（CSCs）在治疗心肌病方面具有疗效，但干细胞疗法仍存在许多局限性。已证明CSC衍生的外泌体（CSC-XOs）是CSCs大部分再生作用的原因。我们使用阿霉素诱导的扩张型心肌病小鼠模型，研究了向小鼠全身递送人CSC-XOs的效果。接受CSC-XOs的小鼠通过超声心动图显示心脏功能得到改善，同时细胞凋亡和纤维化减少。尽管使用了免疫健全的小鼠和人CSC-XOs，但小鼠未表现出不良免疫反应。使用CSC-XOs有望克服干细胞的局限性并改善心脏治疗。
Zotero 插件